Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure

A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released by the U.S. FDA stating that saxagliptin and alogliptin might increase the risk of heart failure, in particular in patients who have other risk factors for heart failure. The product safety information in the U.S. and Canada were recently updated to include this risk.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Résumé de l’examen de l’innocuité - Inhibiteurs de la dipeptidylpeptidase-4 (DPP-4) - Évaluation du risque potentiel d’insuffisance cardiaque
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2017-06-15 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Résumé de l'examen de l'innocuité", "Dipeptidylpeptidase-4", "DPP-4", "inhibiteurs", "évaluation", "risque", "insuffisance cardiaque", "saxagliptine", "alogliptine", "autres facteurs de risque"], "en": ["Summary Safety Review", "Dipeptidylpeptidase-4", "DPP-4", "Inhibitors", "assessing", "risk", "heart failure", "saxagliptin", "alogliptin", "other risk factors"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source